SynthesisIranian journal of medical sciences2026
Efficacy and Safety of Combined Carbazochrome Sodium Sulfonate and Tranexamic Acid for Blood Loss Control in Patients Undergoing Total Hip Arthroplasty: A Systematic Review and Meta-Analysis.
Synthesis in Iranian journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Total hip arthroplasty (THA) relieves pain and restores function in severe hip arthritis and other painful hip disorders. THA is successful; however, it involves significant perioperative blood loss, which can lead to complications and economic burden. Tranexamic acid (TXA) reduces blood loss. However, its impact on hidden blood loss (HBL) is uncertain. The hemostatic effect of TXA may be enhanced by carbazochrome sodium sulphate (CSS). This study aimed to evaluate the safety and efficacy of combined CSS and TXA in reducing blood loss in THA. Methods: This systematic review and meta-analysis was conducted in accordance with the Cochrane Handbook and PRISMA guidelines. We included randomized controlled trials comparing CSS+TXA versus TXA alone in patients undergoing primary THA. Four electronic databases (MEDLINE via PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials) were searched from inception to 22 May 2024 without language restrictions. The risk of bias was assessed using the Cochrane ROB2 tool. Data were synthesized using mean difference (MD) or relative risk (RR) with 95% confidence intervals. Fixed- or random-effects models were applied based on the level of heterogeneity. Outcomes assessed included total (TBL), hidden (HBL), and intraoperative blood loss (IBL); mean hemoglobin (Hb) reduction; inflammatory markers; visual analogue scale (VAS) pain levels; hospital stay; transfusion rates; and complications. Results: This analysis included 450 participants from three studies. The meta-analysis revealed that the CSS+TXA group had significantly lower TBL (MD=-270.23 mL; P<0.001) and HBL (MD=-269.09 mL; P<0.001) than the TXA+Placebo group. However, there was no significant difference in IBL (MD=-82 mL; P=0.61). The CSS+TXA group had a lower transfusion rate (RR=0.10; P=0.006). Mean Hb reduction, hospital stay, and operation time were not significantly different. CSS+TXA also significantly reduced postoperative VAS pain and inflammatory markers. There was no increase in thromboembolic events or other complications. Conclusion: The combination of CSS and TXA reduces postoperative blood loss, pain, and inflammation in patients undergoing THA, without increasing complications. Further research is required to validate these findings in larger, more diverse populations, and to determine optimal dosing and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.